Season 1 – Episode 3 – The Business of Beauty

TOPICS COVERED

• How aesthetic medicine became a $25–30 billion global industry
• Why there are more med spas in the US than McDonald’s locations
• How device financing quietly shapes which treatments get recommended
• The difference between high-volume and premium-positioning business models
• Why dramatic outcomes trend on social media and subtle ones don’t
• How treatment menus, memberships, and packages are engineered for revenue
• What patients should ask themselves before accepting any recommendation

The Business of Beauty

When people talk about beauty, the conversation is usually emotional. Confidence, aging, self-image, choice. All of that is real. But medical aesthetics is not only personal. It is also economic, and zooming out to see the economics changes how you understand every trend, every treatment plan, and every consultation you will ever sit through.

The global medical aesthetics market is projected to exceed $25 to $30 billion in the next few years. Some projections place it even higher. It is one of the fastest-growing sectors in medicine. When something grows that fast, incentives grow with it. That is not cynical. It is just how markets work. When demand rises, supply expands. When profits increase, competition intensifies. When competition intensifies, messaging gets louder.

There are estimates that there are more med spas in the US than there are McDonald’s. Sit with that for a second. More medical aesthetic clinics than fast food chains. That does not happen by accident. It happens because there is demand, money, and scalability. Beauty is emotional, but beauty is also economics, and economics shapes behavior. It shapes what devices get developed. It shapes what treatments get pushed. It shapes what shows up on your Instagram feed. It even shapes which conversations happen inside consultation rooms.

Aesthetics tends to be framed as artistry, empowerment, and confidence. Sometimes it is. But it is also inventory. It is investment. It is financial structures, growth projections, and return on capital. None of that is inherently bad. Innovation often follows growth. But once you understand that this is a multi-billion-dollar industry rather than a collection of glamorous before-and-after photos, you start seeing it differently.

How We Got Here

Some of this growth is cultural. People live on camera now. High-definition lenses, front-facing phones, Zoom meetings on loop. Appearances have never been more visual, and social media adds a constant comparison layer on top of that.

But a lot of it is structural. The barrier to opening a med spa in many states is much lower than people realize. In some states, non-physicians can own aesthetics practices through management service organizations. Private equity has entered the space. Franchise models have emerged. Device companies offer financing structures that make six-figure equipment surprisingly accessible. When financing is available, expansion accelerates.

Unlike traditional medicine, aesthetic medicine is largely cash-based. No insurance. No prior authorizations. No reimbursement battles. That combination makes it attractive to entrepreneurs, investors, large health care systems, and people who are not in medicine at all. High consumer demand, cash-based revenue, scalable service models, aggressive marketing, and social media amplification add up to rapid growth. Rapid growth changes hiring practices, training, pricing strategies, and the tone of marketing.

Again, none of this is inherently good or bad. It is economics. But aesthetic medicine sits at the intersection of health care, beauty, and business, which means it operates differently than most people assume. It is not just a doctor and syringes. It is capital, branding, positioning, and market competition. That shapes behavior inside the industry. Once you understand how the business works behind the scenes, you start asking different questions. Why is this treatment suddenly everywhere? Why does pricing vary so much? Why does one office push prevention at 25 and another one says to wait? Why are trends accelerating?

Two Medical Worlds, Side by Side

Dr. Eisenstat practices in two different worlds every week. One is anesthesia. The other is aesthetic medicine. Traditional medicine is heavily regulated, insurance-based, protocol-driven, reimbursement-controlled. There are prior authorizations, coverage battles, hospital oversight, layers of compliance. It is slow, structured, and constrained by design.

Aesthetic medicine is the opposite. Cash-based, market-driven, consumer-facing, brand-sensitive. No insurance company deciding what qualifies. No hospital committee approving a laser purchase. Just demand, supply, and choice. That creates freedom. It also creates market pressure. When medicine intersects with market pressure, behavior shifts. Not because people are bad, but because incentives matter. Once you understand the incentives, you start understanding why certain treatments seem to explode overnight, why devices suddenly appear everywhere, why messaging across offices sounds so similar, and why restraint becomes more valuable rather than less.

Why That New Laser Is Everywhere

If you see a new laser suddenly appearing on every med spa website, that is not random. Medical devices are expensive. Aesthetic lasers range anywhere from $80,000 to well over $200,000, sometimes much more depending on configuration. That is not a small purchase. It is capital investment, and most of these devices are not bought outright in cash. They are financed. Five-year terms, monthly payments, trade-in structures, upgrade incentives. Once a practice signs the agreement, there is a fixed monthly cost attached to that device every single month, whether it is used or not.

This is where economics quietly walks into the treatment room. If you have a six-figure device with a monthly payment attached, there is natural pressure to use it. Not because anyone is unethical, but because of how businesses work. There is a behavioral economics concept called sunk cost bias: once you invest heavily in something, you are more likely to justify its use, even subconsciously. So when a treatment is suddenly being marketed everywhere, it is worth asking whether what you are seeing is innovation or adoption pressure.

Device companies compete aggressively. Aesthetics trade shows feel like fashion week for lasers. Every booth claims better results, less downtime, more collagen, more revolutionary technology. Real innovation exists. Marketing also exists. When a device is launched, there is often a surge of early adopters, then social media fills with posts, and patients start asking for the device by name. Now the cycle feeds itself. Demand drives adoption. Adoption drives marketing. Marketing drives demand. If you are sitting in a consultation room, it is worth knowing that part of what you are being offered is influenced by capital structure. That does not mean the recommendation is wrong. It just means it is not purely artistic, which is often how people enter the room expecting it to be. There is math behind it, and understanding that math changes how you interpret trends.

Injectables as Inventory

Injectables are where the business becomes quieter but more consistent. Unlike a laser with one large capital purchase, injectables are inventory. They are ordered, stored, tracked, reordered. Every syringe has a wholesale cost to the practice, which varies by product and volume agreements.

When a patient pays for a syringe of filler or a unit of Botox, the price covers more than the product. It covers the injector’s expertise, the consultation, the medical training, practice overhead, and yes, margin. That is not controversial. Every medical service has a margin. But injectables are different from most traditional medicine because they are discretionary and consumer-driven. No insurance company is approving the dose. No hospital billing department is involved. No external regulator is monitoring quantity.

So what determines how much gets used? Clinical judgment, aesthetic philosophy, and sometimes volume models. Some practices operate on high-volume, low-price structures. Others operate on lower-volume, higher-margin structures. Neither is automatically unethical. They simply create different incentives. A volume model needs to move more units. A premium-positioning model needs fewer treatments at higher pricing. Different strategies shape different aesthetic outcomes.

Here is where it gets uncomfortable. Injectables are scalable. You can add more syringes to a treatment plan far more easily than you can justify a new surgery. When trends shift toward fuller cheeks, sharper jaw lines, and more projection, the question becomes whether that shift is anatomy-driven or market-driven. There was a period, and everyone saw it, when faces became ambitious. Larger midfaces, heavier lower thirds, more structure, less softness. That did not happen in a vacuum. It happened during an era of social media amplification, viral before-and-afters, and aggressive filler education courses. Education itself is good. But when growth and visibility reward dramatic change, subtlety loses. Subtlety does not photograph as dramatically as volume. More change equals more engagement. More engagement equals more visibility. More visibility equals more demand.

This is not an accusation of practices or people. It is about understanding systems. Once you understand the systems behind injectables, the syringe itself is neutral. The philosophy behind it is not. When volume becomes normalized, something else follows: correction cycles.

The Correction Cycle

Over the past several years, there has been a noticeable rise in dissolving procedures. Patients come in asking to reverse filler that was placed years prior. Sometimes trends changed. Sometimes the face changed. Sometimes migration has become visible. Sometimes what looked good at 30 no longer looks right at 42. This is where the long game matters. Filler does not always disappear on the timeline we expect. MRI studies have shown that hyaluronic acid fillers can persist longer than previously assumed. Not always visibly, but structurally they are there. When layering happens over years without a long-term plan, fullness accumulates.

This is not about what is good or bad. It is biology plus business plus time. Injectables are powerful tools that require extreme restraint, and restraint is not always rewarded in a volume-driven environment. Subtle work does not trend. Dramatic change trends. If social media visibility drives patient flow, dramatic outcomes become unintentionally incentivized.

Then something cultural happens. The same platforms that rewarded volume begin to reward reversal. You hear people saying, “I’m dissolving my filler,” “I’m going back to natural,” “I’m undoing everything I’ve done.” The cycle shifts. Expansion, correction, minimalism, expansion again. The market responds to whatever attention rewards. This is why philosophy matters more than ever. The syringe is neutral. Without long-term vision, anatomical understanding, and complication management expertise, the same tool produces very different outcomes.

Menus Are Built, Not Curated

Patients rarely think about treatment menus, but they should. You visit a website and see full-face rejuvenation, liquid facelift, prevention packages, membership pricing, skin clubs, collagen-boost series. Those are not there by accident. They were built strategically by smart business people who understand psychology and marketing. Once a practice understands its fixed costs like rent, payroll, devices, and inventory, it needs predictable revenue. Predictable revenue stabilizes a business. How do you create predictability in an elective, cash-based industry? You bundle. You package. You tier. You create memberships. You encourage maintenance cycles.

This is not sinister. Gyms do it. Salons do it. Subscription services do it. But this is still medicine, and medicine inside a subscription model behaves differently than medicine inside a hospital. When a practice creates something called a full-face rejuvenation package, it is defining the problem broadly. Not a line. Not a shadow. The whole face. When a practice creates a prevention plan at 25, it is expanding the market. When it offers memberships, it is smoothing revenue. These are smart business strategies. They also shape the language, and language shapes perception. If you are told you need a “collagen-banking program,” that frames aging as something that must be actively defended against. If a consultation addresses “the entire face,” that frames aging as global. Once a problem is defined broadly, the solutions expand, and expanded solutions increase revenue.

When you sit in a consultation, you are not just sitting across from a clinician. You are sitting inside a business model. That does not mean the clinician does not care. It means care and commerce coexist, and the structure around the clinician influences how recommendations are delivered. A high-volume practice usually runs consultations quickly. A premium-positioning practice usually runs them slowly and with more curation. A membership-built practice emphasizes maintenance. A dramatic-transformation practice normalizes larger treatment plans. Different models, different energy, different outcomes. The average patient does not see the model. They only see the menu. Once you understand that the menus are engineered, you start listening differently. Is this recommendation about me and my anatomy, or is it about the structure of this practice? That question alone changes how you participate in aesthetic medicine.

Social Media: The Most Powerful Force in the Room

Social media is probably the single most powerful force shaping aesthetic medicine right now. Aesthetic medicine is extremely visual, and visual industries behave differently than other parts of health care.

Start with before-and-after photos. Most people assume those images represent fixed truth. They do not. Timing matters. Immediately after filler there is swelling. Immediately after a neuromodulator kicks in there is a peak smoothness. Immediately after laser there can be temporary tightening from inflammation. Lighting matters. Angles matter. Camera lens distortion matters. A slight shift in the jaw, a head tilt, overhead lighting versus side lighting, all of it changes how a face reads. None of this is necessarily deceptive, but it is curated. When you scroll through dozens of curated transformations in a few seconds, your brain quietly recalibrates what normal looks like.

Social comparison theory tells us that humans evaluate themselves relative to others. On Instagram, the others are filtered, lit, and strategically selected. Modern research on image-based platforms shows higher appearance dissatisfaction the more time users spend comparing. Layer that on top of a multi-billion-dollar, cash-based, fast-growing industry and you get rapid acceleration.

Then add influencer partnerships. Dr. Eisenstat has been approached many times for influencer exchanges. Free treatment for visibility. Product alignment in exchange for exposure. She gets the appeal. She also asks herself the same question every time: if this patient were not posting about it, would I still recommend it in the same way? That question matters, because once marketing enters the treatment room, even subtly, it influences tone. When a treatment goes viral, offices feel pressure to offer it. When a dramatic transformation gains traction, subtlety becomes harder to sell. When an influencer with perfect lighting says something completely changed her life, the context disappears.

The part no one wants to say out loud is that virality is not a credential. A million views does not equal anatomical mastery. A trending reel does not equal complication management. A beautifully curated grid does not equal long-term vision. Social media rewards drama. Medicine requires restraint. Those two values do not always align.

The Business Pressure No One Talks About

The business pressure inside aesthetic medicine is rarely discussed, but it is everywhere. When an industry grows rapidly, expectations grow with it. Revenue targets. Expansion plans. Second locations. Additional providers. Device upgrades. New service launches. Growth becomes the metric, and growth requires momentum. There is constant push for new devices, new injectables, new protocols, new buzzwords, new bundles, because new sells.

But medicine is not fashion. Faces do not need seasonal updates. In a competitive market, novelty attracts attention, so practices feel pressure to evolve constantly. Add in memberships, subscription skin programs, packaged bundles, and tiered rejuvenation plans. Predictable revenue stabilizes a business, but predictable revenue also subtly shapes recommendations. When a practice depends on memberships, maintenance gets emphasized. When expansion is underway, revenue has to cover payroll. When a new device has been purchased, utilization has to justify it.

Business pressure does not automatically create unethical behavior. It creates momentum, and momentum influences pace. In aesthetic medicine, pace matters. Business moves quickly. Faces do not. When those speeds do not match, tension forms. Most patients never see the tension. They see the recommendation in front of them. Once you understand that aesthetic medicine sits inside both medicine and market pressure, you see the environment differently. Providers are navigating more than anatomy. They are navigating economics, and navigating economics requires philosophy.

Where Integrity Lives in a Fast-Growing Industry

Multi-billion-dollar industry. Rapid growth. Capital investment. Inventory models. Bundled menus. Social media acceleration. Internal pressure to expand. None of this makes aesthetic medicine wrong. It makes it powerful, and powerful industries require steady hands.

Businesses move quickly. Faces do not. Faces change slowly. They age gradually. They hold history gradually. But the industry around them moves at an almost infinite speed, with launch cycles, quarterly targets, trend waves, and viral moments. When those two speeds collide, philosophy becomes everything. Not skill alone. Not technology alone. Philosophy. Restraint. Long-term thinking. The ability to zoom out when the market is zooming in. The willingness to say “not yet,” “less,” or “no, we need to wait,” even when acceleration would be easier.

Once you understand the incentives, you stop being surprised by trends. You stop being rushed by urgency. You stop confusing visibility with mastery. Virality is not a credential. Momentum is not wisdom. The future of aesthetic medicine belongs to providers who understand both anatomy and economics, who can sit inside a business model without being driven entirely by it, who understand that growth is exciting but integrity is stabilizing.

Beauty will always be personal. It will always be emotional. But it also exists inside a system of capital, marketing, growth, competition, and momentum. That is what makes it powerful, and powerful industries require discernment. Faces take time to change. So as a physician inside this industry, Dr. Eisenstat believes patients and providers both have to start thinking long-term. Choose from clarity, not urgency.

None of this is about rejecting the industry. It is about understanding it. Once you understand the business of beauty, you participate in it differently. You ask better questions. You notice when a recommendation fits your face and when it fits a business plan. You stop chasing the treatment everyone else is chasing. You trust providers who know when to slow down.

If this episode gave you a new way to think about your next consultation, Dr. Eisenstat would love to hear from you. Find her on Instagram, send a DM, or leave a review. For anyone curious about what thoughtful, restraint-led aesthetic medicine actually looks like in practice, the team is at Line Eraser MD in Livingston, New Jersey.